Regeneron Pharmaceuticals REGN Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's other income, net (note 6)?
- Regeneron Pharmaceuticals (REGN) reported other income, net (note 6) of $201.2M in Q1 2026.
- How has Regeneron Pharmaceuticals's other income, net (note 6) changed year-over-year?
- Regeneron Pharmaceuticals's other income, net (note 6) decreased by 37.5% year-over-year, from $322M to $201.2M.
- What is the long-term trend for Regeneron Pharmaceuticals's other income, net (note 6)?
- Over 3 years (2022 to 2025), Regeneron Pharmaceuticals's other income, net (note 6) has grown at a 111.5% compound annual growth rate (CAGR), from $179.3M to $1.7B.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.